Literature DB >> 32789495

Extensive peritumoral edema and brain-to-tumor interface MRI features enable prediction of brain invasion in meningioma: development and validation.

Leehi Joo1, Ji Eun Park1, Seo Young Park2, Soo Jung Nam3, Young-Hoon Kim4, Jeong Hoon Kim4, Ho Sung Kim1.   

Abstract

BACKGROUND: Brain invasion by meningioma is a stand-alone criterion for tumor atypia in the 2016 World Health Organization classification, but no imaging parameter has yet been shown to be sufficient for predicting it. The aim of this study was to develop and validate an MRI-based radiomics model from the brain-to-tumor interface to predict brain invasion by meningioma.
METHODS: Preoperative T2-weighted and contrast-enhanced T1-weighted imaging data were obtained from 454 patients (88 patients with brain invasion) between 2012 and 2017. Feature selection was performed from 3222 radiomics features obtained in the 1 cm thickness tumor-to-brain interface region using least absolute shrinkage and selection operator. Peritumoral edema volume, age, sex, and selected radiomics features were used to construct a random forest classifier-based diagnostic model. The performance was evaluated using the areas under the curves (AUCs) of the receiver operating characteristic in an independent cohort of 150 patients (29 patients with brain invasion) between 2018 and 2019.
RESULTS: Volume of peritumoral edema was an independent predictor of brain invasion (P < 0.001). The top 6 interface radiomics features plus the volume of peritumoral edema were selected for model construction. The combined model showed the highest performance for prediction of brain invasion in the training (AUC 0.97; 95% CI: 0.95-0.98) and validation sets (AUC 0.91; 95% CI: 0.84-0.98), and improved diagnostic performance over volume of peritumoral edema only (AUC 0.76; 95% CI: 0.66-0.86).
CONCLUSION: An imaging-based model combining interface radiomics and peritumoral edema can help to predict brain invasion by meningioma and improve the diagnostic performance of known clinical and imaging parameters.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  MRI; brain invasion; machine learning; meningioma; radiomics

Mesh:

Year:  2021        PMID: 32789495     DOI: 10.1093/neuonc/noaa190

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  12 in total

1.  Principal component analysis of texture features for grading of meningioma: not effective from the peritumoral area but effective from the tumor area.

Authors:  Teiji Tominaga; Kei Takase; Naoko Mori; Shunji Mugikura; Toshiki Endo; Hidenori Endo; Yo Oguma; Li Li; Akira Ito; Mika Watanabe; Masayuki Kanamori
Journal:  Neuroradiology       Date:  2022-08-31       Impact factor: 2.995

Review 2.  A Spotlight on the Role of Radiomics and Machine-Learning Applications in the Management of Intracranial Meningiomas: A New Perspective in Neuro-Oncology: A Review.

Authors:  Lara Brunasso; Gianluca Ferini; Lapo Bonosi; Roberta Costanzo; Sofia Musso; Umberto E Benigno; Rosa M Gerardi; Giuseppe R Giammalva; Federica Paolini; Giuseppe E Umana; Francesca Graziano; Gianluca Scalia; Carmelo L Sturiale; Rina Di Bonaventura; Domenico G Iacopino; Rosario Maugeri
Journal:  Life (Basel)       Date:  2022-04-14

3.  Radiomics Features Predict Telomerase Reverse Transcriptase Promoter Mutations in World Health Organization Grade II Gliomas via a Machine-Learning Approach.

Authors:  Shengyu Fang; Ziwen Fan; Zhiyan Sun; Yiming Li; Xing Liu; Yuchao Liang; Yukun Liu; Chunyao Zhou; Qiang Zhu; Hong Zhang; Tianshi Li; Shaowu Li; Tao Jiang; Yinyan Wang; Lei Wang
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

4.  A Clinical Prognostic Model Based on Preoperative Hematological and Clinical Parameters Predicts the Progression of Primary WHO Grade II Meningioma.

Authors:  Peng Gao; Tengxiao Kong; Xuqiang Zhu; Yingwei Zhen; Hongjiang Li; Di Chen; Shanpeng Yuan; Dongtao Zhang; Henan Jiao; Xueyuan Li; Dongming Yan
Journal:  Front Oncol       Date:  2021-10-11       Impact factor: 6.244

5.  A Clinical Semantic and Radiomics Nomogram for Predicting Brain Invasion in WHO Grade II Meningioma Based on Tumor and Tumor-to-Brain Interface Features.

Authors:  Ning Li; Yan Mo; Chencui Huang; Kai Han; Mengna He; Xiaolan Wang; Jiaqi Wen; Siyu Yang; Haoting Wu; Fei Dong; Fenglei Sun; Yiming Li; Yizhou Yu; Minming Zhang; Xiaojun Guan; Xiaojun Xu
Journal:  Front Oncol       Date:  2021-10-22       Impact factor: 6.244

6.  Diagnosis of Invasive Meningioma Based on Brain-Tumor Interface Radiomics Features on Brain MR Images: A Multicenter Study.

Authors:  Dongdong Xiao; Zhen Zhao; Jun Liu; Xuan Wang; Peng Fu; Jehane Michael Le Grange; Jihua Wang; Xuebing Guo; Hongyang Zhao; Jiawei Shi; Pengfei Yan; Xiaobing Jiang
Journal:  Front Oncol       Date:  2021-08-20       Impact factor: 6.244

Review 7.  Use of advanced neuroimaging and artificial intelligence in meningiomas.

Authors:  Norbert Galldiks; Frank Angenstein; Jan-Michael Werner; Elena K Bauer; Robin Gutsche; Gereon R Fink; Karl-Josef Langen; Philipp Lohmann
Journal:  Brain Pathol       Date:  2022-03       Impact factor: 6.508

Review 8.  Beyond Glioma: The Utility of Radiomic Analysis for Non-Glial Intracranial Tumors.

Authors:  Darius Kalasauskas; Michael Kosterhon; Naureen Keric; Oliver Korczynski; Andrea Kronfeld; Florian Ringel; Ahmed Othman; Marc A Brockmann
Journal:  Cancers (Basel)       Date:  2022-02-07       Impact factor: 6.639

Review 9.  Molecular Biology in Treatment Decision Processes-Neuro-Oncology Edition.

Authors:  Andra V Krauze; Kevin Camphausen
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

10.  AI-Driven Image Analysis in Central Nervous System Tumors-Traditional Machine Learning, Deep Learning and Hybrid Models.

Authors:  A V Krauze; Y Zhuge; R Zhao; E Tasci; K Camphausen
Journal:  J Biotechnol Biomed       Date:  2022-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.